BRAF Kinase Inhibitors Market

Global BRAF Kinase Inhibitors Market Size, Share And Trend Analysis Report, By Drug (Vemurafenib, Dabrafenib, Lifirafenib, and Encorafenib), By Indication (Metastatic Melanoma, Metastatic Lung Cancer, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), Forecast (2021-2027)
    Update Available - Forecast 2024-2030   

Published: Jul 2023 | Report Code: OMR2025370 | Category : Pharmaceuticals | Delivery Format: /

The global BRAF kinase inhibitors market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). BRAF is a kinase enzyme that helps control cell growth and signalling. This enzyme can be found in a mutated form in some types of cancer, including melanoma and colorectal cancer. Blocking mutated BRAF kinase proteins helps to stop the cancer cells from growing. Some BRAF kinase inhibitors are used to treat cancer. The major factor that is expected to drive the global BRAF kinase inhibitors market during the forecast period includes product approvals by regulatory bodies in various regions across the globe. 

Moreover, the robust pipeline of BRAF kinase inhibitor drugs is expected to significantly drive the growth of the global BRAF kinase inhibitors market during the forecast period. Furthermore, the global BRAF kinase inhibitors market is anticipated to witness high growth during the forecast period, owing to the increasing incidence and prevalence of metastatic cancer. 

The global BRAF kinase inhibitors market analysis includes some of the key market players such as F. Hoffmann-La Roche AG, Novartis International AG, and Pfizer, Inc., among others. To maintain a strong position in the market, these market players are adopting various strategic moves, such as product launches, partnerships, collaborations, and mergers and acquisitions. 

Recent Development

For instance, in June 2020, BeiGene, Ltd., a commercial-stage biotechnology company and SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced the presentation of preclinical data and provided a program update on their ongoing Phase 1b/2 study evaluating the combination of BeiGene’s investigational RAF dimer inhibitor, lifirafenib, with SpringWorks’ investigational MEK inhibitor, mirdametinib, in patients with advanced or refractory solid tumors harbouring mutations in the MAPK pathway, including those with RAS mutations.

Market Coverage

  • The market number available for – 2020-2027
  • Base year- 2020
  • Forecast period- 2021-2027
  • Segment Covered
  • Regions Covered- Globally

Competitive Landscape: F. Hoffmann-La Roche AG, Novartis International AG, and Pfizer, Inc., among others.

Key questions addressed by the report

  • What is the market growth rate?
  • Which segment and region dominates the market in base year?
  • Which segment and region will project fastest growth in the market?
  • How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

  • Who is the leader in the market?
  • How players are addressing challenges to sustain growth?
  • Where is the investment opportunity?

Global BRAF Kinase Inhibitors Market by Segment

By Drug 

Vemurafenib

Dabrafenib

Lifirafenib

Encorafenib

By Indication 

Metastatic Melanoma

Metastatic Lung Cancer

Others

By Distribution Channel 

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Global BRAF Kinase Inhibitors Market by Regional Analysis

North America

  • United States
  • Canada

Europe

  • UK
  • Germany
  • Italy
  • Spain
  • France
  • Rest of Europe 

Asia-Pacific

  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific 

Rest of the World